The fund has exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight OxThera, Prokarium. Among the most successful fund investment fields, there are Genetics, Health Care.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Flerie Invest, startups are often financed by SLS Venture, HealthCap, Q-Med. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Sunstone Life Science Ventures, Riyadh Valley Company. In the next rounds fund is usually obtained by Riyadh Valley Company, Korea Investment Partners, Biotechnology and Biological Sciences Research Council.
The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year.
Related Funds
| Fund Name | Location |
| Atreides Management, LP | Boston, Massachusetts, United States |
| Bainian Kangcheng | China, Ningbo, Zhejiang |
| Beijing Phoenix Wealth Holding Group | - |
| Connectivity Ventures Fund | New York, New York, United States |
| Global Risk Technologies | County Dublin, Dublin, Ireland |
| HDFC Group | - |
| Highland Creek Partners | Canada, Ontario, Toronto |
| Horizen Ventures | Bangalore, India, Karnataka |
| Humanity United | California, San Francisco, United States |
| IIFL | India, Maharashtra, Mumbai |
| InnoSpace | China, Hong Kong, Hong Kong Island |
| LongLing Capital | China, Fujian, Xiamen |
| M. R. Al Khathlan | - |
| Revolution Ventures | District of Columbia, United States, Washington |
| Shunfeng Photovoltaic | Changzhou, China, Zhejiang |
| Slant Design + Marketing Inc. | British Columbia, Canada, Vancouver |
| Sonae | Maia, Porto, Portugal |
| Talwalkars | India, Maharashtra, Mumbai |
| Welsh Development Agency | Cardiff, United Kingdom, Wales |
| Wright Flyer Live Entertainment | Chiba Prefecture, Japan, Tateyama |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Synerkine Pharma | $6M | 12 Oct 2023 | Utrecht, Utrecht, Netherlands | ||
Prokarium | $30M | 09 Feb 2023 | London, England, United Kingdom | ||
Vitara Biomedical | $75M | 13 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
AnaCardio | $18M | 07 Sep 2022 | Solna, Stockholms Lan, Sweden | ||
Geneos Therapeutics | $17M | 24 Mar 2022 | Whitemarsh Township, Pennsylvania, United States | ||
Microbiotica | $68M | 07 Feb 2022 | Cambridge, England, United Kingdom | ||
Synerkine Pharma | $4M | 16 Dec 2021 | Utrecht, Utrecht, Netherlands | ||
EpiEndo Pharmaceuticals | $23M | 18 Aug 2021 | Iceland, Iceland | ||
| $21M | 27 Oct 2020 | London, England, United Kingdom |
– EpiEndo Pharmaceuticals announced the closing of a €20m Series A financing round.
– The round was led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council joining the round.
– The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
– EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in propagating chronic inflammatory diseases in lungs and contributes to vulnerability to infections associated with acute exacerbations of airway diseases.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Synerkine Pharma | $6M | 12 Oct 2023 | Utrecht, Utrecht, Netherlands | ||
Prokarium | $30M | 09 Feb 2023 | London, England, United Kingdom | ||
Vitara Biomedical | $75M | 13 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
AnaCardio | $18M | 07 Sep 2022 | Solna, Stockholms Lan, Sweden | ||
Geneos Therapeutics | $17M | 24 Mar 2022 | Whitemarsh Township, Pennsylvania, United States | ||
Microbiotica | $68M | 07 Feb 2022 | Cambridge, England, United Kingdom | ||
Synerkine Pharma | $4M | 16 Dec 2021 | Utrecht, Utrecht, Netherlands | ||
EpiEndo Pharmaceuticals | $23M | 18 Aug 2021 | Iceland, Iceland | ||
| $21M | 27 Oct 2020 | London, England, United Kingdom |
